MedElevator Войти в исследования
← Поиск публикаций

DOI 10.23736/s2724-5683.20.05289-5

Медицинская библиотека · Minerva cardiology and angiology · 2021

Meta-analysis of impact of renin-angiotensin system inhibitors on survival after transcatheter aortic valve implantation.

Takagi Hisato, Kuno Toshiki, Hari Yosuke, Nakashima Kouki, Yokoyama Yujiro, Ueyama Hiroki, Ando Tomo, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group

СтатьяМетаанализПеревод пока не подготовлен

Аннотация

INTRODUCTION

To determine whether renin-angiotensin system inhibitor (RASI) prescription is associated with better survival after transcatheter aortic valve implantation (TAVI), we performed the first meta-analysis of currently available studies.

EVIDENCE ACQUISITION: To identify all studies reporting impact of RASI prescription on survival after TAVI, we searched PubMed, Web of Science, Google Scholar, etc. through October 2019. We extracted adjusted (if unavailable, unadjusted) hazard ratios (HRs) with their confidence intervals (CIs) of midterm (up to ≥6-month) all-cause mortality for RASI prescription from each study and combined study-specific estimates using inverse variance-weighted averages of logarithmic HRs in the random-effects model.

EVIDENCE SYNTHESIS: We identified 13 eligible studies with a total of 26,132 TAVI patients and included them in the present meta-analysis. None was a randomized controlled trial, 5 were observational studies comparing patients with versus without RASI prescription (including 3 propensity score matched studies), and 8 were observational studies investigating RASI prescription as one of covariates. The primary meta-analysis of all studies demonstrated that RASI prescription was associated with significantly lower midterm mortality (HR=0.83; 95% CI: 0.76 to 0.92; P=0.0002). Although we identified significant funnel plot asymmetry (P=0.036 by the rank correlation test) suggesting publication bias, correcting for it using the trim-and-fill method did not substantially alter the result favoring RASI prescription (corrected HR=0.85; 95% CI: 0.76 to 0.95; P=0.004).

CONCLUSIONS

RASI prescription may be associated with better midterm survival after TAVI.

Для цитирования: Takagi Hisato, Kuno Toshiki, Hari Yosuke, Nakashima Kouki, Yokoyama Yujiro, Ueyama Hiroki, Ando Tomo, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Meta-analysis of impact of renin-angiotensin system inhibitors on survival after transcatheter aortic valve implantation.. Minerva cardiology and angiology. 2021. DOI: 10.23736/s2724-5683.20.05289-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.